innoscripta SE (ISIN: DE000A40QVM8) has reported a robust first half of 2026, with revenue climbing 43% year-on-year to EUR 63.1 million. Adjusted EBIT rose 49% to EUR 36.4 million, excluding EUR 535 thousand in non-recurring expenses tied to corporate restructuring and the establishment of the group structure. The adjusted EBIT margin reached 57.7%, underscoring the company's operational efficiency.
Central to this performance is Clusterix, innoscripta's scalable software platform for managing research and development (R&D) activities. The company has further strengthened Clusterix as its central infrastructure, enabling automated data validation, higher data quality, and standardized workflows across different markets. This technological foundation is critical for the company's international scaling efforts.
The German R&D tax allowance (Forschungszulage) remains a key growth driver, and the number of customers has grown to more than 2,900 during the period. This growth is part of a broader trend where companies are increasingly leveraging digital tools to manage innovation projects and claim tax incentives.
Geographically, innoscripta has executed its expansion strategy with precision. The company opened an office in Hamburg, Germany, and established its first French location near Toulouse, already securing customers. In the UK, a Manchester office was opened as of 01 July 2026, and the company has begun serving clients in the US, a high-growth market. The adaptability of Clusterix to different regulatory requirements has enabled efficient entry into these new markets.
Looking ahead, the Management Board confirms its guidance for the current financial year, expecting revenue of at least EUR 140 million and EBIT of at least EUR 80 million, assuming consistent timing of customer application submissions and approvals. The company's half-year report is available on its website in the Investors section, and a virtual earnings call is scheduled for today at 3:00 p.m. CEST.
These results highlight innoscripta's position as a key player in the R&D management software space, with a business model that benefits from regulatory tailwinds and a scalable platform. The successful international expansion and strong financial performance underscore the company's potential for continued growth.
